DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

More Industry Headlines

Study finds tomosynthesis is ultimately less expensive than digital mammography Diagnosis-related costs need to be considered

Kubtec to supply X-ray technology for 3,500 year-old tomb excavation Will assess tomb of ancient Greek warrior

California Proton Therapy Center re-launches California Protons Consists of new management and leadership and an expanded group of physicians

IBM Watson Health tackles EMR challenges at RSNA Showcased new product and upgrade in current technology

CT study gives further pause about possible football health risks High rate of enlarged aortas increase risk of life-threatening aneurysm

Researchers develop MR technique to predict and prevent pregnancy complications Tracking water molecules to assess placenta health

Dignity Health, Catholic Health Initiatives agree to merge into giant, new Catholic health system Will provide care in 28 states

IBM Watson Health unveils breast advisors solution at RSNA Uses imaging analytics

Edwards acquires Harpoon Medical Company now owns the image-guiding HARPOON System

Philips acquires VitalHealth for an undisclosed amount Adds to its population health management portfolio

IBA spin-off, Novation ink PET radiopharmaceutical deal

by Brendon Nafziger , DOTmed News Associate Editor
Ion Beam Applications S.A.'s newly spun-off radiopharmaceutical wing IBA Molecular has inked a five-year deal with group purchasing organization Novation LLC to supply its member health care facilities with PET radiotracers.

Under the deal, announced Monday, IBA Molecular will supply imaging agents, including 18-Fluorodeoxyglucose, as well as provide educational and training services. The contract took effect July 1. Terms of the deal weren't disclosed.

Story Continues Below Advertisement

Putting Your Enterprise Imaging Strategy in Place:

8 Tips for Selecting the Right Transformation Partner. As the healthcare industry moves toward a more personalized, value-based care model, choosing the right solution partner to obtain a truly transformational enterprise imaging strategy is paramount.



IBA Molecular has 54 PET isotope facilities in Europe, North America and Asia. It also delivers agents for SPECT imaging worldwide.

SK Capital Partners holds a controlling stake in IBA Molecular, which was spun off from its Belgian parent company, which retains a minority stake, in April.

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED